share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4：持股變動聲明-高管 Gibson Christopher
美股SEC公告 ·  08/24 05:27
牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals, Inc. CEO Christopher Gibson acquired 5,000 shares of the company's Class A Common Stock on 08/23/2024. The transaction was executed at a price of $2.48 per share, indicating a total investment of $12,400. Following this purchase, Gibson's direct holdings in the company increased to 737,656 shares. The transaction, which is currently in progress, was reported as an exercise or conversion of derivative security.
Recursion Pharmaceuticals, Inc. CEO Christopher Gibson acquired 5,000 shares of the company's Class A Common Stock on 08/23/2024. The transaction was executed at a price of $2.48 per share, indicating a total investment of $12,400. Following this purchase, Gibson's direct holdings in the company increased to 737,656 shares. The transaction, which is currently in progress, was reported as an exercise or conversion of derivative security.
Recursion Pharmaceuticals公司首席執行官Christopher Gibson於2024年08月23日收購了該公司的5000股A類普通股。每股價格爲2.48美元，總投資金額爲12400美元。在此次購買後，Gibson在公司的直接持股增至737,656股。這筆交易目前正在進行中，被報告爲衍生證券的行權或轉換。
Recursion Pharmaceuticals公司首席執行官Christopher Gibson於2024年08月23日收購了該公司的5000股A類普通股。每股價格爲2.48美元，總投資金額爲12400美元。在此次購買後，Gibson在公司的直接持股增至737,656股。這筆交易目前正在進行中，被報告爲衍生證券的行權或轉換。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間